GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
CytoMed Therapeutics Ltd revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Reportable segments [member] | 324.39K SGD | 69.50K SGD | – | – | – | 100.0% | +366.7% |
| CBU service & related therapy [member] | 324.39K SGD | 69.50K SGD | – | – | – | 100.0% | +366.7% |
By product or service
By region
From the segment and revenue-disaggregation notes of CytoMed Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.